Xcovery

Xcovery LLC is a biopharmaceutical company based in Palm Beach Gardens, Florida, founded in 2006. It specializes in the development of targeted oncology therapies designed to address various advanced tumors. The company is known for its lead compound, X-396, a small molecule that inhibits anaplastic lymphoma kinase, along with other kinase inhibitors targeting MET and PI3K/mTOR pathways. Xcovery aims to create low-toxicity oral drugs that facilitate continuous therapy without the need for dosing interruptions, thereby enhancing treatment efficacy and safety for cancer patients. This approach allows for a broader therapeutic window and the potential for combination therapies without the toxicity associated with current treatments. The leadership team includes experienced professionals from notable biotech backgrounds, contributing to the company's innovative research and development efforts in oncology.